These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 26972187)
41. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients. Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411 [TBL] [Abstract][Full Text] [Related]
42. Diagnostic tools in Sezary syndrome. Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046 [TBL] [Abstract][Full Text] [Related]
43. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571 [TBL] [Abstract][Full Text] [Related]
44. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Su T; Duran GE; Kwang AC; Ramchurren N; Fling SP; Kim YH; Khodadoust MS Oncoimmunology; 2022; 11(1):2115197. PubMed ID: 36046812 [TBL] [Abstract][Full Text] [Related]
45. Drug-induced pseudo-Sezary syndrome: a case report and literature review. Reeder MJ; Wood GS Am J Dermatopathol; 2015 Jan; 37(1):83-6. PubMed ID: 25033012 [TBL] [Abstract][Full Text] [Related]
46. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. Yoo EK; Cassin M; Lessin SR; Rook AH J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181 [TBL] [Abstract][Full Text] [Related]
49. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity. Nevet MJ; Zuckerman T; Sahar D; Bergman R Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993 [TBL] [Abstract][Full Text] [Related]
50. The molecular pathogenesis of mycosis fungoides and Sézary syndrome. Döbbeling U G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211 [TBL] [Abstract][Full Text] [Related]
52. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. Huet D; Bagot M; Loyaux D; Capdevielle J; Conraux L; Ferrara P; Bensussan A; Marie-Cardine A J Immunol; 2006 Jan; 176(1):652-9. PubMed ID: 16365461 [TBL] [Abstract][Full Text] [Related]
53. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice. van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578 [TBL] [Abstract][Full Text] [Related]
54. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102 [TBL] [Abstract][Full Text] [Related]
55. Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells. Chong BF; Dantzer P; Germeroth T; Hafner M; Wilson AJ; Xiao G; Wong HK J Dermatol Sci; 2010 Oct; 60(1):8-20. PubMed ID: 20801618 [TBL] [Abstract][Full Text] [Related]